UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMCShionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available Share XUK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMChttps://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/
ICER says ‘marginal’ benefits for AbbVie’s new RA drugAbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as Share XICER says ‘marginal’ benefits for AbbVie’s new RA drughttps://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/
After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEAfter more than 20 years of challenging pharma over drug prices, Sir Andrew Dillon is to step down Share XAfter two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEhttps://pharmaphorum.com/news/after-two-decades-taking-on-pharma-over-price-sir-andrew-dillon-steps-down-from-nice/
Scotland’s cost regulator rejects Vertex cystic fibrosis drugsScotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of Share XScotland’s cost regulator rejects Vertex cystic fibrosis drugshttps://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/
NICE recommends funding for psoriasis and type 1 diabetes drugsPatients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended Share XNICE recommends funding for psoriasis and type 1 diabetes drugshttps://pharmaphorum.com/news/nice-recommends-funding-for-psoriasis-and-type-1-diabetes-drugs/
J&J’s Spravato for depression ‘should be much cheaper’Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer Share XJ&J’s Spravato for depression ‘should be much cheaper’https://pharmaphorum.com/news/jjs-spravato-for-depression-should-be-much-cheaper/
NICE rejects Alnylam and Akcea’s amyloidosis drugsNICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft Share XNICE rejects Alnylam and Akcea’s amyloidosis drugshttps://pharmaphorum.com/news/nice-rejects-alnylam-and-akceas-amyloidosis-drugs/
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICENICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective Share XAbbVie’s CLL drug Venclyxto too expensive for NHS, says NICEhttps://pharmaphorum.com/news/abbvies-cll-drug-venclyxto-too-expensive-for-nhs-says-nice/
Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
